Results 251 to 260 of about 260,886 (316)

Jaceosidin inhibits cell viability and induces apoptosis in non-small cell lung cancer by inhibiting the Ras/Raf/MEK/ERK and Akt pathways. [PDF]

Oncol Lett
Cao X, Ma C, Wang X, Wang C, Shen L, Wei J, Yang R, Li Y, He X, Chen L.   +9 more
europepmc   +1 more source

LINC00886 inhibits the proliferation, migration, and invasion of NSCLC cells by sponging miR-141-5p. [PDF]

Discov Oncol
Liang X, Guan X.
europepmc   +1 more source

Lung, NSCLC

Annals of Oncology, 1998
openaire   +1 more source

TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with <i>EGFR</i>-mutated locally advanced or metastatic non-small cell lung cancer. [PDF]

Ther Adv Med Oncol
Lu S, Pulla MP, Mascarenhas E, Tanizaki J, Kim HR, Liu Y, Feng S, Zhang B, Toms L, Yang JC, Goldberg SB.   +10 more
europepmc   +1 more source

Genetic influence of PPAR-γ rs1801282 and MTRR rs162036 variants on non-small cell lung cancer risk in Egyptians. [PDF]

Discov Oncol
Metwally YF, Zahran RF, El Sadda RR, Refaat S, Elsaid AM.   +4 more
europepmc   +1 more source

Oligometastatic NSCLC

Oncology Times, 2019
openaire   +2 more sources

YY1-mediated NDUFA9 upregulation promotes NSCLC cell growth through mitochondrial and Akt-mTOR pathway modulation. [PDF]

Cell Death Dis
Yan Y, Zhao Y, Tang J, Wang X, Zhao J, Yang Y.   +5 more
europepmc   +1 more source